Application and Prospect of Payment for Performance Risk-Sharing Arrangements for Medical Device in China

China Health Insurance ›› 2023, Vol. 0 ›› Issue (2) : 123-128.

China Health Insurance ›› 2023, Vol. 0 ›› Issue (2) : 123-128. DOI: 10.19546/j.issn.1674-3830.2023.2.019
Medical Economy

Application and Prospect of Payment for Performance Risk-Sharing Arrangements for Medical Device in China

Author information +
History +

Abstract

Rapid development of medical devices introduces the concern of value uncertainty, and payment for performance risk-sharing arrangements (RSA) can help address uncertainty concerns of payers and medical institutions. This study summarized the payment for performance RSA cases for medical devices both at home and abroad, and analyzed key elements to be considered in medical devices payment for performance, including closely combining with healthcare policies, satisfying key stakeholders’ needs, selecting proper medical devices and scope, and establishing RSA scheme design and implementation. Based on local and global experience as well as current policy, this paper analyzed the application and prospect of payment for performance RSA to support the value access for medical devices and promote the use of innovative medical devices in the context of DRG/DIP in China.

Key words

pay for performance / risk-sharing agreements / medical device / value access

Cite this article

Download Citations
Application and Prospect of Payment for Performance Risk-Sharing Arrangements for Medical Device in China[J]. China Health Insurance. 2023, 0(2): 123-128 https://doi.org/10.19546/j.issn.1674-3830.2023.2.019

References

[1] 国家医疗保障局.关于《基本医疗保险医用耗材支付管理暂行办法(征求意见稿)》《医保医用耗材“医保通用名”命名规范(征求意见稿)》公开征求意见的公告[EB/OL].(2021-11-19)[2023-02-01]. http://www.nhsa.gov.cn/art/2021/11/19/art_113_7352.html.
[2] GONCALVES F R, SANTOS S, SILVA C, et al.Risk-sharing agreements, present and future. Ecancermedicalscience[J].2018,12:823.
[3] BANZI R, GERARDI C, BERTELE' V, et al. Approvals of drugs with uncertain benefit-risk profiles in Europe. Eur J Intern Med[J].2015,26(8):572-584.
[4] TARAKJI K G, MITTAL S, KENNERGREN C.et al., Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med[J].2019,380(20):1895-1905.
[5] JOE CARTSON. Medtronic’s Tyrx envelopes aimed at reducing heart device infections[EB/OL].(2017-06-10)[2023-02-01]. https://www.startribune.com/medtronic-s-tyrx-envelopes-aimed-at-reducing-heart-device-infections/427535213/?refresh=true.
[6] 卢才荣,章贤莉,姜小燕,等.同伴支持对2型糖尿病患者胰岛素泵使用依从性和生活质量的影响[J].基层医学论坛,2022,26(14):1-3.
[7] ALEX KACIK. Medtronic inks outcome-based contract with Aetna for insulin pumps[EB/OL].(2017-06-26)[2023-02-01]. https://www.modernhealthcare.com/article/20170626/NEWS/170629914/medtronic-inks-outcome-based-contract-with-aetna-for-insulin-pumps.
[8] SUSAN KELLY. Medtronic, United Healthcare say value-based pact cut diabetes costs[EB/OL].(2018-07-11)[2023-02-01]. https://www.medtechdive.com/news/medtronic-unitedhealthcare-say-value-based-pact-cut-diabetes-costs/527496/.
[9] 上海市医疗保障局.关于部分诊疗项目试行按绩效支付的通知[EB/OL].(2021-04-09)[2023-02-01]. https://ybj.sh.gov.cn/qtwj/20210414/a4d9d5b7509c4dca99489d6f6fce6e07.html.
[10] 上海市医疗保障局.关于部分诊疗项目试行按绩效支付的通知[EB/OL].(2021-01-12)[2023-02-01]. https://ybj.sh.gov.cn/qtwj/20220120/d85cb2c5f04c44cd8fa871b2ad904003.html.
[11] 上海市医疗保障局.关于部分医用耗材试行按绩效支付的通知[EB/OL].(2022-05-18)[2023-02-01]. http://ybj.sh.gov.cn/qtwj/20220519/ad620ec0be714247b43cbf87ca53c7f2.html.
[12] 新华社.浙江试点肝移植术基本医保按绩效支付[EB/OL].(2017-12-09)[2023-02-01].http://www.gov.cn/xinwen/2017-12/09/content_5245565.htm.
[13] Medtronic.厦门大学附属第一医院与美敦力共同推出价值医疗战略实践:门诊动态调糖项目[EB/OL].(2019-03-15)[2023-02-01].https://www.medtronic.com/cn-zh/about/news/VBHC_Xiamen_Project.html.
[14] GARRISON LP JR, TOWSE A, BRIGGS A, et al.Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health[J].2013,16(5):703-719.
[15] CARLSON J J, GRIES K S, YEUNG K, et al.Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy[J].2014,12(3):231-238.

Accesses

Citation

Detail

Sections
Recommended

/